Trials / Completed
CompletedNCT01153542
Study of VX-770 on Desipramine
An Open-Label Phase 1 Study to Examine the Effect of VX 770 on Desipramine in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to evaluate the effects of VX-770 on Desipramine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-770 | In period 1, subjects will receive a single oral dose of desipramine on Day 1. |
| DRUG | VX-770 | In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2010-06-30
- Last updated
- 2010-12-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01153542. Inclusion in this directory is not an endorsement.